Tennant Company heads into its May 5 Q1 2026 earnings print with short sellers adding positions at the fastest pace in months — even as the stock has staged a sharp recovery.
The short-side buildup is the clearest pre-earnings signal. Short interest climbed 39% over the past month to 6.2% of the free float, with the weekly pace of accumulation accelerating to nearly 7%. That move has been accompanied by a jump in borrowing costs: cost to borrow more than doubled over the same period, reaching 0.92% — still cheap in absolute terms, but the direction is unmistakable. Availability has tightened as well, now at its 52-week extreme. The ORTEX short score nudged above 52 in the final days of April, its highest level over the measured period, confirming the trend. What makes this notable is the timing: shorts have been building throughout the month even as the stock rallied 17% from its April lows to close at $81.95 on Monday.
Options positioning adds another layer of caution. The put/call ratio is running at 2.46 — well above historical norms for this name and near a multi-week high — though the z-score of 0.51 suggests this level has become something of a sustained baseline rather than an acute spike. The combination of an elevated PCR and a rising short position paints a picture of investors paying meaningful premiums for downside protection even after a strong price recovery.
The bull-bear debate centres on whether the recent order-book momentum can translate into reported revenue. Bulls point to North American order growth running ahead of GDP for the fifth consecutive quarter and expanding autonomous cleaning unit deployments. Bears counter with Q2 2025 results that missed consensus by roughly $8 million, a 5.5% organic sales decline, and ongoing softness in international markets — particularly Mexico — where demand weakness has yet to fully clear. Analyst coverage remains thin. The most recent action, from February 2026, saw Freedom Broker downgrade to Hold and slash its target from $93 to $67, while Roth Capital maintained Buy but trimmed its target to $91. With the stock now trading at $81.95 — above the Roth target after the recent rally — the upside story requires a meaningful re-rating to hold.
Insider activity from early March offers the most constructive counter-signal. Director James Glerum bought roughly $500,000 of stock at $61.25 in early March, and independent director Don Mulligan added $185,000 the same week — both purchases made near the lows, now sitting on gains of roughly 34%. That cluster of buying adds credibility to the recovery narrative, though the same directors and executives conducted routine sells in late February and mid-April at similar prices.
The print will test whether the order growth the company highlighted entering the year has survived the macro cross-currents, and whether management can address the operational issues that depressed revenue in prior quarters — the answers will determine whether the short-side conviction heading into today's release is well-placed or overextended.
See the live data behind this article on ORTEX.
Open TNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
